REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Net Revenues	$ 614,376	$ 486,816	$ 316,385
Rare Disease total net revenues
Disaggregation of Revenue [Line Items]
Net Revenues	229,599	112,117	41,686
Cortrophin Gel
Disaggregation of Revenue [Line Items]
Net Revenues	198,085	112,117	41,686
ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Net Revenues	31,514	0	0
Rare Disease and Brands total net revenues
Disaggregation of Revenue [Line Items]
Net Revenues	294,342	197,501	81,148
Brands
Disaggregation of Revenue [Line Items]
Net Revenues	64,743	85,384	39,462
Generics and Other total net revenues
Disaggregation of Revenue [Line Items]
Net Revenues	320,034	289,315	235,237
Generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Net Revenues	301,004	269,449	210,120
Royalties and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Net Revenues	$ 19,030	$ 19,866	$ 25,117